Insider Selling: Illumina, Inc. (ILMN) Director Sells 825 Shares of Stock
Illumina, Inc. (NASDAQ:ILMN) Director Frances Arnold sold 825 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $174.77, for a total transaction of $144,185.25. Following the sale, the director now directly owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 1.24% during trading on Friday, reaching $175.91. The company’s stock had a trading volume of 959,273 shares. The stock’s 50 day moving average price is $179.07 and its 200 day moving average price is $157.94. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48. The company has a market cap of $25.68 billion, a PE ratio of 35.60 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. The firm had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.71 EPS. Equities research analysts predict that Illumina, Inc. will post $3.63 EPS for the current year.
A number of equities analysts have recently weighed in on the company. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 target price on the stock in a report on Tuesday. Leerink Swann upped their target price on Illumina from $134.00 to $138.00 and gave the company a “market perform” rating in a report on Thursday, February 9th. Morgan Stanley reiterated an “underweight” rating and issued a $115.00 target price (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. Canaccord Genuity reiterated a “hold” rating and issued a $150.00 target price on shares of Illumina in a report on Tuesday, February 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $155.00 target price on shares of Illumina in a report on Wednesday, February 1st. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Illumina has a consensus rating of “Hold” and an average price target of $165.02.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC raised its position in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares during the period. Edgewood Management LLC raised its position in Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock valued at $850,157,000 after buying an additional 1,671,293 shares during the period. Norges Bank bought a new position in Illumina during the fourth quarter valued at $140,899,000. Capital World Investors raised its position in Illumina by 37.1% in the third quarter. Capital World Investors now owns 2,006,100 shares of the life sciences company’s stock valued at $364,428,000 after buying an additional 543,100 shares during the period. Finally, Viking Global Investors LP bought a new position in Illumina during the fourth quarter valued at $44,810,000. 92.79% of the stock is currently owned by hedge funds and other institutional investors.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.